In recent years, the activity of anaesthetic propofol on biological processes has been attracting attention. The effect of propofol on biochemical indices in animals is unknown. In this study, we examined the effects of propofol on lipid profile, antioxidant indices, and cardiovascular marker (CVM) enzymes in rats. The study consists of three groups of seven rats each. Group one received corn oil (Control) while groups two and three received propofol (doses of 2 and 4？mg/kg body weight, resp.). Results showed that administration of propofol caused a significant ( ) and dose-dependent increase in the levels of total bilirubin. Propofol at 2 and 4？mg/kg increased the levels of serum total cholesterol by 74% and 55%, triglycerides by 97% and 115%, and LDL-C (low-density lipoprotein-cholesterol) by 45% and 73%, respectively, while HDL-C (high-density lipoprotein-cholesterol) decreased by 41% and 54%, respectively. Propofol significantly ( ) increased the levels of the hepatic reduced glutathione (GSH) and activities of GSH-dependent enzymes. Propofol at 2 and 4？mg/kg increased the activities of CVM enzymes: lactate dehydrogenase by 1.7 and 1.8 folds and creatinine phosphokinase by 2.0 and 2.1 folds, respectively. Taken together, propofol increased the levels of GSH and GSH-dependent enzymes but adversely affected the lipid profile of the rats. 1. Introduction Oxidative stress can be described as an imbalance between the production of free radicals and antioxidant defence. Over the last decades, it has become amply evident that oxidative stress, usually in the form of reactive oxygen species (ROS), is a critical pathogenic factor in the development of several systemic diseases [1, 2]. Therefore, inhibition of ROS formation, scavenging of ROS, or interfering with ROS pathogenic signaling pathways might be the potential ways to protect against oxidative stress-induced ailments [3]. Propofol (2,6-diisopropylphenol) (Figure 1), a highly lipid-soluble anaesthetic, is widely used for induction and maintenance of general anaesthesia. Propofol ameliorates oxidative injury in several organs, including the heart [4], lungs [5], brain [6], liver [7], and testis [8]. Propofol is chemically similar to the endogenous antioxidant α-tocopherol (vitamin E) and, theoretically, it should have similar properties [9]. It is not surprising therefore that many studies have demonstrated antioxidant effects of propofol in vitro [10–12] and in vivo [13]. Propofol has also been shown to elicit antiapoptotic effect in human umbilical vein endothelial cells by acting as an antioxidant
References
[1]
Y. Kouidrat, A. Amad, R. Desailloud, et al., “Increased advanced glycation end-products (AGEs) assessed by skin autofluorescence in schizophrenia,” Journal of Psychiatry Research, 2013.
[2]
B. Das, P. C. Maity, and A. K. Sil, “Vitamin C forestalls cigarette smoke induced NF-κB activation in alveolar epithelial cells,” Toxicology Letter, vol. 220, no. 1, pp. 76–81, 2013.
[3]
J. Y. Lee and M. C. Kim, “Effect of propofol on oxidative stress status in erythrocytes from dogs under general anaesthesia,” Acta Veterinaria Scandinavica, vol. 54, no. 1, pp. 76–78, 2012.
[4]
Y. C. Tsai, C. C. Huang, L. M. Chu, and Y. C. Liu, “Differential influence of propofol on different cell types in terms of the expression of various oxidative stress-related enzymes in an experimental endotoxemia model,” Acta Anaesthesiologica Taiwanica, vol. 50, no. 4, pp. 159–166, 2012.
[5]
L. Ma, X. Y. Wu, L. H. Zhang, et al., “Propofol exerts anti-inflammatory effects in rats with lipopolysaccharide-induced acute lung injury by inhibition of CD14 and TLR4 expression,” Brazilian Journal of Medical and Biological Research, vol. 46, no. 3, pp. 299–305, 2013.
[6]
X. Qin, Z. Q. Sun, X. W. Zhang, X. J. Dai, S. S. Mao, and Y. M. Zhang, “TLR4 signaling is involved in the protective effect of propofol in BV2 microglia against OGD/reoxygenation,” Journal of Physiology and Biochemistry, 2013.
[7]
H. Wang, Z. Xue, Q. Wang, X. Feng, and Z. Shen, “Propofol protects hepatic l02 cells from hydrogen peroxide-induced apoptosis via activation of extracellular signal-regulated kinases pathway,” Anesthesia and Analgesia, vol. 107, no. 2, pp. 534–540, 2008.
[8]
A. ünsal, E. Devrim, C. Guven et al., “Propofol attenuates reperfusion injury after testicular torsion and detorsion,” World Journal of Urology, vol. 22, no. 6, pp. 461–465, 2004.
[9]
L. Aarts, R. van der Hee, I. Dekker, J. de Jong, H. Langemeijer, and A. Bast, “The widely used anaesthetic agent propofol can replace alpha-tocopherol as an antioxidant,” FEBS Letter, vol. 357, no. 1, pp. 83–85, 1995.
[10]
M. Tesauro, W. C. Thompson, and J. Moss, “Effect of staurosporine-induced apoptosis on endothelial nitric oxide synthase in transfected COS-7 cells and primary endothelial cells,” Cell Death and Differentiation, vol. 13, no. 4, pp. 597–606, 2006.
[11]
B. Wang, T. Luo, D. Chen, and D. M. Ansley, “Propofol reduces apoptosis and up-regulates endothelial nitric oxide synthase protein expression in hydrogen peroxide-stimulated human umbilical vein endothelial cells,” Anesthesia and Analgesia, vol. 105, no. 4, pp. 1027–1033, 2007.
[12]
J.-J. Xu and Y.-L. Wang, “Propofol attenuation of hydrogen peroxide-mediated oxidative stress and apoptosis in cultured cardiomyocytes involves haeme oxygenase-1,” European Journal of Anaesthesiology, vol. 25, no. 5, pp. 395–402, 2008.
[13]
K. Kobayashi, F. Yoshino, S. S. Takahashi, et al., “Direct assessments of the antioxidant effects of propofol medium chain triglyceride/long chain triglyceride on the brain of stroke-prone spontaneously hypertensive rats using electron spin resonance spectroscopy,” Anesthesiology, vol. 109, no. 3, pp. 426–435, 2008.
[14]
T. Ito, Y. Mishima, A. Ito et al., “Propofol protects against anandamide-induced injury in human umbilical vein endothelial cells,” Kurume Medical Journal, vol. 58, no. 1, pp. 15–20, 2011.
[15]
O. H. Lowry, N. J. Rosebrough, A. L. Farr, and R. J. Randall, “Protein measurement with the Folin phenol reagent,” The Journal of Biological Chemistry, vol. 193, no. 1, pp. 265–275, 1951.
[16]
A. F. Mohun and I. J. Cook, “Simple methods for measuring serum levels of the glutamic-oxalacetic and glutamic-pyruvic transaminases in routine laboratories,” Journal of Clinical Pathology, vol. 10, no. 4, pp. 394–399, 1957.
[17]
S. Reitman and S. Frankel, “A colorimetric method for the determination of serum glutamic oxalacetic and glutamic pyruvic transaminases,” American Journal of Clinical Pathology, vol. 28, no. 1, pp. 56–63, 1957.
[18]
R. Walls, K. S. Kumar, and P. Hochstein, “Aging of human erythrocytes. Differential sensitivity of young and old erythrocytes to hemolysis induced by peroxide in the presence of thyroxine,” Archives of Biochemistry and Biophysics, vol. 174, no. 2, pp. 463–468, 1976.
[19]
M. S. Moron, J. W. Depierre, and B. Mannervik, “Levels of glutathione, glutathione reductase and glutathione S-transferase activities in rat lung and liver,” Biochimica et Biophysica Acta, vol. 582, no. 1, pp. 67–78, 1979.
[20]
J. M. McCord and I. Fridovich, “Superoxide dismutase. An enzymic function for erythrocuprein (hemocuprein),” Journal of Biological Chemistry, vol. 244, no. 22, pp. 6049–6055, 1969.
[21]
H. Aebi, “Catalase,” in Methods of Enzymatic Analysis, H. V. Bergmeyer, Ed., pp. 673–684, Verlag Chemie, New York, NY, USA, 1974.
[22]
W. H. Habig, M. J. Pabst, and W. B. Jakoby, “Glutathione S transferases. The first enzymatic step in mercapturic acid formation,” Journal of Biological Chemistry, vol. 249, no. 22, pp. 7130–7139, 1974.
[23]
J. T. Rotruck, A. L. Pope, H. E. Ganther, A. B. Swanson, D. G. Hafeman, and W. G. Hoekstra, “Selenium: biochemical role as a component of glatathione peroxidase,” Science, vol. 179, no. 4073, pp. 588–590, 1973.
[24]
S. Okinaka, H. Kumagai, S. Ebashi et al., “Serum creatine phosphokinase. Activity in progressive muscular dystrophy and neuromuscular diseases,” Archives of Neurology, vol. 4, no. 1, pp. 520–525, 1961.
[25]
H. J. Zimmerman and B. S. Weinstein, “Lactic dehydrogenase activity in human serum,” The Journal of Laboratory and Clinical Medicine, vol. 48, no. 2, pp. 607–609, 1956.
[26]
R. B. Rutkowski and L. DEBaare, “An ultramicro colorimetric method for determination of total and direct serum bilirubin,” Clinical Chemistry, vol. 12, no. 7, pp. 432–438, 1966.
[27]
M. Jaffe, “Ueber den Neiderschlag, welchen Pikrins？ure im normalen harn Erzeught und über eine neue Reaction des Kreatinins,” Journal of Physiological Chemistry, vol. 10, no. 1, pp. 391–400, 1886.
[28]
H. Talke and G. E. Schubert, “Enzymatische Harnstoff bestimmung in Blut and serum in Optischen Test nach Warburg,” Klinische Wochschrift, vol. 43, no. 1, pp. 174–176, 1965.
[29]
W. T. Friedewald, R. I. Levy, and D. S. Fredrickson, “Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge,” Clinical Chemistry, vol. 18, no. 6, pp. 499–502, 1972.
[30]
W. G. Siems, T. Grune, and H. Esterbauer, “4-hydroxynonenal formation during ischemia and reperfusion of rat small intestine,” Life Sciences, vol. 57, no. 8, pp. 785–789, 1995.
[31]
M. Y. Wang, K. Dhingra, W. N. Hittelman, J. G. Liehr, M. De Andrade, and D. Li, “Lipid peroxidation-induced putative malondialdehyde-DNA adducts in human breast tissues,” Cancer Epidemiology Biomarkers and Prevention, vol. 5, no. 9, pp. 705–710, 1996.
[32]
O. A. Adaramoye, O. A. Adesanoye, O. M. Adewumi, and O. Akanni, “Studies on the toxicological effect of nevirapine, an antiretroviral drug, on the liver, kidney and testis of male Wistar rats,” Human and Experimental Toxicology, vol. 31, no. 7, pp. 676–685, 2012.
[33]
W. F. Riesen and R. C. Mordasini, “Update of lipid lowering therapy,” Praxis, vol. 97, no. 22, pp. 1179–1184, 2008.
[34]
L. Ashakumari and P. L. Vijyammal, “Additive effect alcohol and nicotine on lipid metabolism in rats,” Indian Journal of Experimental Biology, vol. 31, pp. 270–274, 1993.
[35]
G. K. Glantzounis, H. J. Salacinski, W. Yang, B. R. Davidson, and A. M. Seifalian, “The contemporary role of antioxidant therapy in attenuating liver ischemia-reperfusion injury: a review,” Liver Transplantation, vol. 11, no. 9, pp. 1031–1047, 2005.
[36]
J. D. Hayes, J. U. Flanagan, and I. R. Jowsey, “Glutathione transferases,” Annual Review of Pharmacology and Toxicology, vol. 45, no. 1, pp. 51–88, 2005.
[37]
G. J. Smith, V. Sapico Ohl, and G. Litwack, “Ligandin, the glutathione S transferases, and chemically induced hepatocarcinogenesis: a review,” Cancer Research, vol. 37, no. 1, pp. 8–14, 1977.
[38]
J. E. Aldrich, “Clinical enzymology,” in Clinical Chemistry: Concept and Applications, S. C. Anderson and S. Cockayne, Eds., pp. 261–284, McGraw Hill, New York, NY, USA, 2003.
[39]
M. R. Hayden and S. C. Tyagi, “Intimal redox stress: accelerated atherosclerosis in metabolic syndrome and type 2 diabetes mellitus. Atheroscleropathy,” Cardiovascular Diabetology, vol. 1, no. 1, pp. 3–8, 2002.
[40]
N. F. Wiernsperger, “Oxidative stress as a therapeutic target in diabetes: revisiting the controversy,” Diabetes and Metabolism, vol. 29, no. 6, pp. 579–585, 2003.
[41]
R. Rej, “Aspartate aminotransferase activity and isoenzyme proportions in human liver tissues,” Clinical Chemistry, vol. 24, no. 11, pp. 1971–1979, 1978.
[42]
E. El Daly, “Effect of methimazole and fish oil treatment on gentamicin hephrotoxicity in rats,” Journal of Islamic Academic of Science, vol. 9, pp. 37–48, 1996.
